ReviewImmunoTargets and therapy2026
New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.
Review in ImmunoTargets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A nephropathy (IgAN) is a chronic disease. Active disease typically presents with massive proteinuria and gross hematuria, along with renal pathological features such as mesangial cell proliferation, endothelial cell proliferation, and crescents. Active lesions may achieve remission following treatment but also can relapse at any stage of the patient's life. Systemic inflammatory markers are significantly associated with IgAN disease activity indicators. Research has found that patients with high disease activity and low chronicity are more likely to benefit from immunosuppressive therapy. We speculated that "four-hit" hypothesis in IgAN may exist as the background for the recurrence of the disease. Bacterial or viral infections and vaccinations are common mucosal triggers that may induce active lesions by activating systemic inflammatory responses. The clinical manifestations triggered by these factors are diverse, which likely reflects the complex interplay between the nature of the injury and individual patient susceptibility. In this narrative review, we explore new insight on IgAN from the perspective of active disease and systemic inflammatory responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.